Table 10.
Genotype frequencies of four polymorphisms in ONFH patients in the relation to number of affected joints (total, unilateral and bilateral ONFH) and controls
| Genotype | Controls N=100 |
Patients |
||
|---|---|---|---|---|
| Total N=68 | Unilateral n=29 | Bilateral n=39 | ||
| Factor V Leiden | ||||
| GA |
3(3%) |
3(4,41%) |
2(6,89%) |
1(2,56%) |
| GG |
97(97%) |
65(95,59%) |
27(93,11%) |
38(97,44%) |
| Prothrombin | ||||
| GA |
2(2%) |
1(1,47%) |
1(3,44%) |
0 |
| GG |
98(98%) |
67(98,53%) |
28(96,56%) |
39(100%) |
| MTHFR | ||||
| TT |
7(7%) |
4(5,88%) |
2(6,89%) |
2(5,12%) |
| CT |
42(42%) |
35(51,47%) |
14(48,27%) |
21(53,84%) |
| CC |
51(51%) |
29(42,65%) |
13(44,84%) |
16(41,04%) |
| TPA | ||||
| DD |
18(18%) |
13(19,12%) |
3(10,34%) |
10(25,64%)a |
| ID |
37(37%) |
38(55,88%)b |
17(58,62%) |
21(53,84%)c |
| II | 45(45%) | 17(25%) | 9(31,04%) | 8(20,52%) |
ap=0,034; odds ratio (OR) 3,12; 95% confidence intervals (CIs) 1,06-9,18.
bp=0,004; OR 2,71; 95% CIs 1,32-5,57.
cp=0,009; OR 3,19; 95% CIs 1,26-8,03.